Roche spent $1B for the Leading Molecular Information Biotech company: Foundation Medicine

13/01/2015 - 2 minutes

2015 starts in a rush for the Biotech industry. Swiss Pharma-giant Roche just announced paying $1B to acquire 56% percent of leading molecular information and genomic analysis Biotech company Foundation Medicine.

Foundation Medicine is a leading Biotech company in the field of molecular information and genomic analysis. It uses next-gen sequencing technology and solid bioinformatic analysis to find out genetic anomalies in your cancer biopsy. Physicians are then able to know patient’s tumor profile and find the most targeted drug, on the market or in development. In shorter terms, Foundation is contributing to make personalized medicine a reality.


Roche is acquiring Foundation Medicine for its commercial potential but also to accelerate Foundation Medicine’s new product development initiatives, optimize treatments for oncology patients, and better design and understand the results of clinical trials based on molecular information. Indeed, Foundation has a strategic role by knowing which cancer each patients has. It advices the physician on which drug to administer (a Roche one for example) or which drug in clinical trials could benefit the patients (again Roche has a great oncology pipeline).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following: